Search International and National Patent Collections

1. (WO2017054787) PHARMACEUTICAL COMPOSITION COMPRISING THE COMBINATION OF CANDESARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE

Pub. No.:    WO/2017/054787    International Application No.:    PCT/CZ2016/000110
Publication Date: Fri Apr 07 01:59:59 CEST 2017 International Filing Date: Wed Sep 28 01:59:59 CEST 2016
IPC: A61K 31/41
A61K 31/4178
A61K 31/4184
A61K 31/4245
A61K 31/4422
A61K 31/4439
A61K 31/496
A61K 31/549
A61P 9/12
Applicants: ZENTIVA, K.S.
Inventors: KHULLAR, Praveen
PRASAD, Kum
KOTHAWADE, Kishor
GUPTA, Prashant
DEVARAJAN, Saravanan
DEOLIA, Santosh Kumar
SACHIN, Kalsotra
Title: PHARMACEUTICAL COMPOSITION COMPRISING THE COMBINATION OF CANDESARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE
Abstract:
The present invention relates to a composition for preventing or treating cardiovascular disorders comprising the combination of candesartan of formula (I), chemically 2-ethoxy-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-1,3-benzodiazole-7-carboxylic acid, or a pharmaceutically acceptable salt thereof, with Hydrochlorothiazide of formula (II), chemically 6-chloro-1,1-dioxo-3,4- dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide, or a pharmaceutically acceptable salt thereof, and Amlodipine of formula (III), chemically 3-ethyl-5-methyl-2-(2-aminoethoxy-methyl)-4-(2-chlorophenyl)- 6-methyl-1,4-dihydro-3,5-pyridine dicarboxylate, or a pharmaceutically acceptable salt thereof, and a method of preparing the same. The choice of these agents and their dosage in the combination regime are designed to enhance the tolerability by minimizing the risk of dose-dependent adverse effects usually associated with individual agents that can be expressively eliminated by the proposed triple combination product. (Formulae (I), (II), (III))